Compare CLMT & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLMT | TYRA |
|---|---|---|
| Founded | 1916 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2024 | 2021 |
| Metric | CLMT | TYRA |
|---|---|---|
| Price | $34.16 | $35.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $28.65 | ★ $47.50 |
| AVG Volume (30 Days) | 845.7K | ★ 1.1M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.39 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,137,100,000.00 | N/A |
| Revenue This Year | $3.94 | N/A |
| Revenue Next Year | $1.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.00 | $8.75 |
| 52 Week High | $36.94 | $40.65 |
| Indicator | CLMT | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 61.11 | 48.11 |
| Support Level | $17.70 | $33.81 |
| Resistance Level | $36.94 | $39.48 |
| Average True Range (ATR) | 1.15 | 2.11 |
| MACD | 0.01 | -0.24 |
| Stochastic Oscillator | 93.32 | 36.28 |
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.